Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 245

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Endothelins in cardiovascular biology and therapeutics

Open access
Dhaun, Neeraj, Webb, David J. · 2019 · Nature Reviews Cardiology

Abstract

Cardiovascular disease is a major contributor to global morbidity and mortality and is the common end point of many chronic diseases. The endothelins comprise three structurally similar peptides of 21 amino acids in length. Endothelin 1 (ET-1) and ET-2 activate two G protein-coupled receptors — endothelin receptor type A (ETA) and endothelin receptor type B (ETB) — with equal affinity, whereas ET-3 has a lower affinity for ETA. ET-1 is the most potent vasoconstrictor in the human cardiovascular system and has remarkably long-lasting actions. ET-1 contributes to vasoconstriction, vascular and cardiac hypertrophy, inflammation, and to the development and progression of cardiovascular disease. Endothelin receptor antagonists have revolutionized the treatment of pulmonary arterial hypertension. Clinical trials continue to explore new applications of endothelin receptor antagonists, particularly in treatment-resistant hypertension, chronic kidney disease and patients receiving antiangiogenic therapies. Translational studies have identified important roles for the endothelin isoforms and new therapeutic targets during development, in fluid-electrolyte homeostasis, and in cardiovascular and neuronal function. Novel pharmacological strategies are emerging in the form of small-molecule epigenetic modulators, biologics (such as monoclonal antibodies for ETB) and possibly signalling pathway-biased agonists and antagonists.Endothelin 1 is the most potent vasoconstrictor in the human cardiovascular system. In this Review, Dhaun and Webb discuss the biology of the endothelins and endothelin receptors and how these pathways can be therapeutically targeted in cardiovascular and renal diseases.Key pointsEndothelin 1 (ET-1) is the most potent endogenous vasoconstrictor and contributes to basal vascular tone as well as a number of diseases, such as hypertension, chronic kidney disease (CKD), pulmonary arterial hypertension (PAH) and pre-eclampsia.A common non-coding gene sequence variant regulates the expression of EDN1 (encoding ET-1) and is linked to five common vascular conditions: coronary artery disease, hypertension, migraine, cervical artery dissection and fibromuscular hyperplasia.The effects of ET-1 are mediated via two G protein-coupled receptors, endothelin receptor type A (ETA) and endothelin receptor type B (ETB); selective ETA and dual ETA/ETB receptor antagonists (endothelin receptor antagonists; ERAs) are available for clinical use.The phase III PRECISION study will explore the use of a long-acting, selective ETA antagonist in treatment-resistant hypertension.For many patients with PAH, ERAs are considered first-line treatment; ERAs also reduce blood pressure and proteinuria in CKD and show clinical potential in scleroderma renal crisis, the transition from acute kidney injury to CKD and end-stage renal disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-019-0176-3

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 245

Metadata

Authors
Dhaun, N., & Webb, D. J.
Venue
Nature Reviews Cardiology
Published
2019-03-13
Volume
16
Issue
8
Pages
491-502
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W2921688102
Cited by
245
References
5
FWCI
5.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endothelins in cardiovascular biology and therapeutics. https://app.cochat.ai/papers/10.1038/s41569-019-0176-3
The paper
Dhaun, N., & Webb, D. J. (2019). Endothelins in cardiovascular biology and therapeutics. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-019-0176-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.